1. Ashwin C, Baron-Cohen S, Wheelwright S, O’Riordan M, Bullmore ET. Differential activation of the amygdala and the “social brain” during fearful face-processing in Asperger syndrome. Neuropsychologia 2007; 45(1): 2–14.
2.
Bahji A, Forsyth A, Grolla D, Hawken ER, Efficacy of 3,4-meth ylenedioxymethamphetamine(MDMA)-assisted psychother apy for posttraumatic stress disorder: A systematic reviewand meta-analysis. Prog Neuropsychopharmacol Biol Psy chiatr 2020; Volume 9610: Article 109735.
3.
Bedi G, Phan KL, Angstadt M, de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) 2009; 207:73–83.
4.
Begola MJ, Schillerstrom JE. Hallucinogens and Their Thera peutic Use: A Literature Review J Psychiatr Pract 2019; 25(5): 334–346.
5.
Bershad AK, Mayo LM, Van Hedger K, McGlone F, Walker SC, de Wit H. Effect of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychophar macology 2019; 44: 1698–1705.
6.
Bershad AK, Miller MA, Baggott MJ, de Wit H. The effects of MDMA on socio-emotional processing: does MDMA dif fer from otherstimulants? J Psychopharmacol 2016; l30:1248–1258 (a).
7.
Bershad AK, Weafer JJ, Kirkpatrick MG, Wardle MC, Miller MA, deWit H. Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc Neurosci 2016; 11: 592–599 (b).
8.
Betzler F, Viohl L, Romanczuk-Seiferth N. Decision-making in chronic ecstasy users: a systematic review. Eur J Neurosci 2017 45 (1): 34–44.
9.
Bouso JC, Doblin R, Farre M, Alcazar MA, Gomez-Jarabo G. MDMA assisted psychotherapy using low doses in a smallsample of women with chronic posttraumatic stress disor der. J Psychoactive Drugs 2008; 40(3): 225–236.
10.
Boxler MI, Liechti ME, Schmid Y et al. First time view on human metabolome changes after a single intake of 3,4meth ylenedioxymethamphetamine in healthy placebo-controlled subjects. J Proteome Res. 2017; 16: 3310–3320.
11.
Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R. Human pharmacology of 3,4-methylenedioxy methamphetamine (“ecstasy”): psychomotorperformance and subjective effects. J Clin Psychopharmacol 2000; 20: 455–466.
12.
Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B i wsp. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity Biol Psychiatry 2015; 78 (8): 554–562.
13.
Clark ChM, Frye ChG, Wardle MC, Norman GJ, de Wit H. Acute Effects of MDMA on Autonomic Cardiac Activity and Their Relation to Subjective Prosocial and Stimulant Effects Psychophysiology 2015; 52(3): 429–35.
14.
Cohen RS. Subjective reports on the effects of the MDMA (‘ecstasy’) experience in humans. Prog Neuropsychophar macol Biol Psychiatry 1995; 19: 1137–1145.
15.
Curran HV, Travill RA. Mood and cognitive effects of ±3,4– methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by mid-week low. Addiction 1997; 92: 821–31.
16.
Dahlgren MK, Laifer L M, VanElzakker MB , Offringa R et al. Diminished medial prefrontal cortex activation during the recollection of stressful events is an acquired character istic of PTSD Psychol Med 2018;48(7):1128-1138
17.
Danforth AL, Grob ChS, Struble Ch, Feduccia AA, Walker N, Jerome L et al. Reduction in social anxiety after MDMA-as sisted psychoterapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychophar macology (Berl). 2018; 235(11): 3137–3148.
18.
Danforth AL, Struble ChM, Yazar-Klosinski B, Grob ChS. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Progress in Neuro-Psychopharma cology & Biological Psychiatry 2016; 64: 237–249.
19.
Dunlap LE, Andrews AM, Olson DE. Dark Classics in Chem ical Neuroscience: 3,4-methylenedioxymethamphetamine. ACS Chemical Neuroscience 2018; 9 (10): 2408–2427.
20.
Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry 2018; 84(A), 8: 221–228.
21.
Foa EB, Riggs DS, Dancu CV, Rothbaum BO. Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. J Trauma Stress 1993, 6, 459–473.
22.
Francati V, Vermetten E, Bremner JD. Functional neuroimag ing studies in posttraumatic stress disorder: review of current methods and findings. Depress Anxiety 2007; 24: 202–218.
23.
Freye E. Pharmacological Effects of MDMA in Man. Phar macology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer Netherlands, 2009.
24.
Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX. 3,4-Methylenedioxymethamphetamine (MDMA) modu lates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology 2000; 23: 388–395.
25.
Garg A, Kapoor S, Goel M, Chopra S, Chopra M, Kapoor A et al. Functional Magnetic Resonance Imaging in AbstinentMDMA Users: A Review. Current Drug Abuse Reviews 2015; 8 (1): 15–25.
26.
Greene SL, Kerr F, Braitberg G. Review article: amphet amines and related drugs of abuse. Emergency Medicine Australasia 2008; 20 (5): 391–402.
27.
Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319–27.
28.
Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: meth odological considerations and preliminary observations. Behav Brain Res 1996; 73: 103–107.
29.
Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxy methamphetamine (MDMA) in humans. Psychopharmacol ogy 2002; 162: 396–405.
30.
Hoshi R, Bisla J, Curran HV. The acute and sub-acute effects of “Ecstasy” (MDMA) on processing of facial expressions: preliminary findings. Drug Alcohol Depend 2004; 76(3): 297–304.
31.
Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 2013; 9: 1645–1652.
32.
Johansen PO, Krebs TS. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J. Psycho pharmacol 2009; 23 (4): 389–391.
33.
Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ 2001; 165(7).
34.
Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H. Ef fects of MDMA and Intranasal Oxytocin on Social and Emo tional Processing Neuropsychopharmacology 2014; 39(7):1654–1663.
35.
Kittler K, Lau T, Schloss P. Antagonists and substrates dif ferentially regulate serotonin transporter cell Surface ex pression in serotonergic neurons. Eur. J. Pharmacol. 2010; 629: 63−67.
36.
Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Plasma pharmacokinetics of 3,4-methylenedi oxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 2008; 30: 320–332.
37.
Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the Potential of Psychedelics for the Treatment of PTSD International Journal of Neuropsycho pharmacology 2020; 20(20): 1–16.
38.
Kuypers KP, Dolder PC, Ramaekers JG, Liechti ME. Multi faceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. J Psychopharmacol (Oxf) 2017; 31: 589-598
39.
Leonardi ET, Azmitia EC. MDMA (ecstasy) inhibition of MAO type A and type B, comparisons with fenfluramine and fluox etine (Prozac). Neuropsychopharmacology 1994; 10: 231−238.
40.
Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001; 154: 161–168.
41.
Lima JPC, Rodrigues AL. Nasal Oxytocin: Facts and Routes. Acta Psychopathol 2019; Vol. 5 No.1: 1.
42.
Martinez-Turrillas R, Moyano S, Del Rio J, Frechilla D. Dif ferential effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) on BDNF mRNA expression in rat frontal cortex and hippocampus. Neurosci. Lett. 2006; 402: 126−130.
43.
Mas M, Farré M, de la Torre R, Roset PN, Ortuno J, Segura J et al. Cardiovascular and neuroendocrine effects and phar macokinetics of 3,4-methylene-dioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290:136–45
44.
McCann UD, Eligulashvili V, Ricaurte GA. (+/-)3,4-Methy lenedioxymeth-amphetamine (‘ecstasy’)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000; 42: 11–16.
45.
Mithoefer MC, A Manual for MDMA-Assisted Psychothera py in the Treatment of Posttraumatic Stress Disorder. Ver sion 8.1 http://www.maps.org/research/mdma/mdma-re search-timeline/4887-a-manual-for-mdma-assisted-psycho therapy-in-the-treatment-of-ptsd 2017 (dostęp 14.06.2020)
46.
Mithoefer MC, Feduccia AA, Jerome L, Mithoefer AT, Mark Wagner M, Walsh Z et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trial. Psychopharmacology 2019; 236: 2735–2745.
47.
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police offi cers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry 2018; Vol. 5, No. 6: p. 486–497.
48.
Mithoefer MC, Mithoefer AT, Jerome L, Ruse J, Doblin R et al.A Manual for MDMA-Assisted Psychotherapy in the Treat ment of Posttraumatic Stress Disorder. Multidisciplinary As sociation for Psychedelic Studies (Version 8.1) 2017; https://s3-us-west-1.amazonaws.com/mapscontent/research-ar chive/mdma/TreatmentManual_MDMAAssistedPsycho therapyVersion+8.1_22+Aug2017.pdf (dostęp 14.06.2020).
49.
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymetham phetamine -assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacology 2010; 25(4): 439-452. [Poźniejsze erraty: J Psychopharma col. 2011; 25(6): 852 J Psychopharmacol. (Oxf.) 2011; 25 (4): 439–452].
50.
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedi oxymethamphetamine assisted psychotherapy: a prospective long term follow-up study. J Psychopharmacol 2013; 27(1): 28–39.
51.
Morgan L. MDMA-assisted psychotherapy for people diag nosed with treatment-resistant PTSD: what it is and what it isn’t. Morgan Ann Gen Psychiatry 2020; 19–33.
52.
Mueller F, Lenz C, Steiner M, Dolder PC, Walter M, Lang UE et al. Neuroimaging in moderate MDMA use: A systematic review. Neurosci. Biobehav. Rev. 2016; 62, 21−34.
53.
Muttoni S, Ardissino M, Ch John. Classical psychedelics for the treatment of depression and anxiety: A systematic re view. J Affect Disord 2019; 258: 11–24.
54.
Nichols DE, Hoffman AJ, Oberlender RA, Jacob P 3rd, Shulgin A.T. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 1986; 29: 2009–2015.
55.
Oehen P, Traber R, Widmer V, Schnyder U. A randomized controlled pilot study of MDMA (+/-3,4-Methylenedioxy methamphetamine) – assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol (Oxf.) 2013; 27(1): 40–52.
56.
Ogden P, Pain C, Fisher J. A sensorimotor approach to the treatment of trauma and dissociation. Psychiatr Clin North Am 2006; 29: 263–279.
57.
Ot’alora GM, Grigsby J, Poulter B, Van Derveer JW, Giron SG, Jerome L et al. 3,4-Methylenedioxymethamphetamine-as sisted psychotherapy for treatment of chronic posttrauma tic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol. (Oxf) 2018; 32(12): 1295–1307.
58.
Pagliaro LA, Pagliaro AM. Child and Adolescent Drug and Substance Abuse: A Comprehensive Reference Guide, Ro utledge 2019.
59.
Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition before, during, and after a Saturday night dance. Psychopharmacology 1998; 139: 261–8.
60.
Parrott AC. The Potential Dangers of Using MDMA for Psy chotherapy. J Psychoactive Drugs 2014; 46: 37–43.
61.
Passie T. Healing with entactogens: Therapist and patient per spectives on MDMA-assisted group psychotherapy. Multidi sciplinary Association for Psychedelic Studies (MAPS), 2012.
62.
Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxy-methamphetamine in recreational users. Neuropsychopharmacology 1988; 1: 273–277.
63.
Pitts EG, Curry DW, Hampshire KN, Young MB, Howell LL. (±)-MDMA and Its Enantiomers: Potential Therapeu tic Advantages of R(-)-MDMA Psychopharmacology (Berl) 2018; 235(2): 377–392.
64.
Próba kliniczna nr: NCT02427568 MDMA-assisted Psy chotherapy for Anxiety Associated With a Life-threate ning Illness https://www.clinicaltrials.gov/ct2/show/NCT02427568?cond=mdma&draw=2&rank=15 (dostęp 22.08.2020).
65.
Próba kliniczna nr NCT04158778: Bristol Imperial MDMA in Alcoholism Study (BIMA) https://clinicaltrials.gov/ct2/show/NCT04158778?cond=mdma&draw=3&rank=38 (do stęp 14.06.2020).
66.
Próba kliniczna nr: NCT04454684 A Multi-site Study of MD MA-Assisted Psychotherapy for Eating Disorders (MED1) https://www.clinicaltrials.gov/ct2/show/NCT04454684?-cond=mdma&draw=2&rank=44 (dostęp 22.08.2020).
67.
Próba kliniczna nr NCT04516902 Effects of MDMA Co-ad ministration on the Response to LSD in Healthy Subjects (LSD-MDMA) https://www.clinicaltrials.gov/ct2/show/NCT04516902?cond=mdma&draw=2&rank=32 (dostęp 22.08.2020).
68.
Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxy methamphetamine (‘ecstasy’)-induced serotonin neurotoxi city: studies in animals. Neuropsychobiology 2000; 42: 5–10.
69.
Schenk S, Newcombe D. Methylenedioxymethamphetamine (MDMA) in Psychiatry Pros, Cons, and Suggestions. J Clin Psychopharmacol 2018; 38 (6): 632–638.
70.
Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME. Differential effects of MDMA and methy lphenidate on social cognition. J Psychopharmacol (Oxf) 2014; 28: 847–856.
71.
Sellers EM, Leiderman DB. Psychedelic Drugs as Therapeu tics: No Illusions About the Challenges. Clinical Pharmaco logy and Therapeutics 2018; 103: 561–564.
72.
Sessa B. Why MDMA therapy for alcohol use disorder? And why now? Neuropharmacology 2018; 142: 83–88.
73.
Sessa B. Why Psychiatry Needs 3,4-Methylenedioxymetham phetamine: A Child Psychiatrist’s Perspective. Neurothera peutics 2017; 14(3): 741–749.
74.
Sessa B, Sakal Ch, O’Brien S, Nutt D. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA) assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Reports, 2019; doi: 10.1136/bcr-2019-230109.
75.
Spates R, Souza T. Treatment of PTSD and Substance Abu se Comorbidity. The Behavior Analyst Today 2007; 9 (1): 11–26.
76.
Spitzer M, Franke B, Walter H, Buechler J, Wunderlich AP, Schwab M et al. Enantio-selective cognitive and brain acti vation effects of N-ethyl3,4-methylenedioxyamphetamine in humans. Neuropharmacology 2001; 41: 263–271.
77.
Stewart SH. Alcohol abuse in individuals exposed to trauma: a critical review. Psychol Bull 1996; 120 (1): 83–112.
78.
Szigeti B, Winstock AR, Erritzoe D, Maier LJ. Are ecsta sy induced serotonergic alterations overestimated for the majority of users? J Psychopharmacol 2018; 32 (7): 741–748.
79.
Tancer M, Johanson CE. The effects of fluoxetine on the sub jective and physiological effects of 3,4-methylenedioxyme thamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2007; 189: 565–573.
80.
de la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J et al. Pharmacology of MDMA in humans. Ann N YAcad Sci 2000; 914: 225–237.
81.
Verebey K, Alrazi J, Jaffe JH. The complications of ‘ecstasy’ (MDMA). JAMA 1988; 259: 1649–1650.
82.
Vollenweider FX, Gamma A, Liechti M, Huber T. Psycholo gical and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241–251.
83.
Weathers FW, Keane TM, Davidson J. Clinician-administe red PTSD scale: A review of the first ten years of research. Depress Anxiety. 2001; 13:132–156.
84.
Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53:1605–1612.
85.
Young MB, Andero R, Ressler KJ, Howell LL. 3,4-Methylene dioxymethamphetamine facilitates fear extinction learning. Transl. Psychiatry 2015; 5, e634.
86.
Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch SAM, Reiff CM et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4methylenedioxymethamphetamine (MDMA) Psychophar macology (Berl) 2017; 234(19): 2883–2895.
